Plain-English translation of NCT06767150 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing the best way to transition women off denosumab—a bone-strengthening medication—and onto zoledronic acid, another bone medication. When women stop denosumab, their bones can temporarily weaken and lose density, even if the medication was working well. The study compares two approaches: one standard approach using one infusion, and one personalized approach that uses blood tests to decide if a second infusion is needed.
When women stop taking denosumab, their bones sometimes rapidly weaken in a 'rebound' effect, which can increase fracture risk. Doctors aren't yet sure how much of the new medication is needed to prevent this bone loss, so this trial is testing whether blood tests can guide better, more personalized treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the medication at scheduled visits over about a year. Some participants will receive one infusion (standard approach), while others will have blood tests to check a bone marker; if your levels show your bones are weakening too much, you'll receive a second infusion. You'll have regular follow-up visits and blood draws to monitor how your bones are responding to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France